

# Biological Activity Investigation of Phytocomponents in Mangosteen (*Garcinia mangostana* L.): *In Silico* Study

Arif Nur Muhammad Ansori<sup>1</sup>, Raden Joko Kuncoroningrat Susilo<sup>2</sup>, Suhailah Hayaza<sup>2</sup>

<sup>1</sup>Doctoral Student, Doctoral Program in Veterinary Science, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia, <sup>2</sup>Doctoral Student, Doctoral Program in Mathematics and Natural Sciences, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia

## Abstract

Indonesia has abundant medicinal plants, which have been historically used by the population in treating diseases for generations. Traditional Indonesian medicine and the medicinal plants used could lead to the discovery of novel drugs. The mangosteen or *Garcinia mangostana* L. is a well-known medicinal plant that has been used to treat various diseases worldwide. The pharmacological activities and phytochemical composition of the whole plant of mangosteen have been investigated and identified by scientists in recent decades. Therefore, this study aims to generate the prediction of the biological activity of phytocomponents in mangosteen. In this study, we extracted 18 phyocomponents of mangosteen from PubChem, an open chemistry database at the National Institutes of Health (NIH), USA. Then, we predicted the pharmacokinetic properties and druglike nature of the phytocomponents using the SwissADME web server, Swiss Institute of Bioinformatics, Swiss. Furthermore, PASS (Prediction of Activity Spectra for Substances) web resource has been employed as a strong potential tool to predict the biological activity. In summary, we revealed the biological activity of 18 phytocomponents of the mangosteen. However, further trials, such as in vitro and in vivo evaluation, are needed to prove the validity of these findings.

**Keywords:** Biological activity, *Garcinia mangostana* L., *in silico*.

## Introduction

Indonesia has rich sources of natural medicines and traditional medicine preparations that have been used by most of the population for generations<sup>[1,2,3]</sup>. A direct advantage of traditional medicine formulations to the community is the ease of obtaining them<sup>[4]</sup>. The demand for plants used as traditional medicine formulations by the community is also increasing because plant-derived medicines have proven to be healthier and do not cause as many side effects as those derived from chemicals. However, a problem with traditional medicine formulations is the lack of adequate knowledge and information about the various types of plants commonly used as ingredients and their methods of use<sup>[5,6]</sup>.

*Garcinia mangostana* L. or mangosteen appertain to the family of Clusiaceae and genus *Garcinia*<sup>[7]</sup>. *Garcinia* is a large genus that consists of around 400 species originated from Malay Peninsula, East India, and Southeast Asia, including Indonesia. Moreover, based on the morphological and cytological studies, it can be suggested that the mangosteen is originated from Southeast Asia<sup>[8]</sup>. As a matter of fact, mangosteen is a plant as traditional medicine for hundreds of years worldwide<sup>[9]</sup>.

Furthermore, mangosteen contains bioactive compounds such as xanthenes, terpenes, anthocyanins, tannins, phenols, and some vitamins<sup>[10,11]</sup>. In fact, mangosteen's pericarp has many important benefits for health<sup>[12,13,14]</sup>. The main compounds in the content of mangosteen's pericarp are xanthenes<sup>[15]</sup>; such as alpha-mangostin<sup>[16]</sup>, gamma-mangostin<sup>[3,17]</sup>, 8-deoxygartanin, garcinone E, mangostanol<sup>[18]</sup>, beta-mangostin<sup>[19]</sup>, tovophyllin A and B<sup>[20]</sup>,

---

### Corresponding author:

Arif Nur Muhammad Ansori

Email: arif.nma-17@fkh.unair.ac.id

mangostenin<sup>[21]</sup>, and mangostenones C, D, and E<sup>[22]</sup>. The main xanthone derivative is alpha-mangostin, this compound has a variety of pharmacological activities such as antidiabetic<sup>[23,24]</sup>, antioxidants, and anti-inflammatory<sup>[12,13,14,25]</sup>. Therefore, this study aims to generate the prediction of the biological activity of phytoconstituents in mangosteen.

## Materials and Methods

### Data retrieval

We extracted 18 phytoconstituents of mangosteen from PubChem, an open chemistry database at the National Institutes of Health (NIH), USA (Table 1). We revealed the Canonical SMILES of the 18 phytoconstituents and submitted them to the SwissADME web server for further analysis.

**Table 1. Phytoconstituents of the mangosteen revealed from the PubChem database.**

No	Compounds	Formula	Molecular Weight
1	Alpha-mangostin	C <sub>24</sub> H <sub>26</sub> O <sub>6</sub>	410.46 g/mol
2	Beta-mangostin	C <sub>25</sub> H <sub>28</sub> O <sub>6</sub>	424.49 g/mol
3	Gamma-mangostin	C <sub>23</sub> H <sub>24</sub> O <sub>6</sub>	396.43 g/mol
4	Gartanin	C <sub>23</sub> H <sub>24</sub> O <sub>6</sub>	396.43 g/mol
5	Garcinone A	C <sub>23</sub> H <sub>24</sub> O <sub>5</sub>	380.43 g/mol
6	Garcinone B	C <sub>23</sub> H <sub>22</sub> O <sub>6</sub>	394.42 g/mol
7	Garcinone C	C <sub>23</sub> H <sub>26</sub> O <sub>7</sub>	414.45 g/mol
8	Garcinone D	C <sub>24</sub> H <sub>28</sub> O <sub>7</sub>	428.47 g/mol
9	Garcinone E	C <sub>28</sub> H <sub>32</sub> O <sub>6</sub>	464.55 g/mol
10	1-Isomangostin	C <sub>24</sub> H <sub>26</sub> O <sub>6</sub>	410.46 g/mol
11	9-Hydroxycalabaxanthone	C <sub>24</sub> H <sub>24</sub> O <sub>6</sub>	408.44 g/mol
12	3-Isomangostin	C <sub>24</sub> H <sub>26</sub> O <sub>6</sub>	410.46 g/mol
13	6-Deoxy-gamma-mangostin	C <sub>23</sub> H <sub>24</sub> O <sub>5</sub>	380.43 g/mol
14	BR-xanthone A	C <sub>23</sub> H <sub>24</sub> O <sub>6</sub>	396.43 g/mol
15	BR-xanthone B	C <sub>14</sub> H <sub>10</sub> O <sub>6</sub>	274.23 g/mol
16	Garcimangosone A	C <sub>28</sub> H <sub>28</sub> O <sub>6</sub>	460.52 g/mol
17	1-Isomangostin hydrate	C <sub>24</sub> H <sub>28</sub> O <sub>7</sub>	428.47 g/mol
18	Calabaxanthone	C <sub>24</sub> H <sub>24</sub> O <sub>5</sub>	392.44 g/mol

### Pharmacokinetics and drug-likeness predictions

In the present study, we predicted the pharmacokinetic properties and druglike nature of the phytochemicals using the SwissADME web server, Swiss Institute of Bioinformatics, Swiss. We identified gastrointestinal absorption prediction for the oral drug probability according to the white of the BOILED-Egg<sup>[26]</sup> and Lipinski parameter for the drug-likeness prediction implemented from Lipinski *et al.* (2001)<sup>[27]</sup>.

### Biological activity prediction

We employed PASS (Prediction of Activity Spectra for Substances) web resource as a strong potential tool to predict the biological activity. This web resource estimates the predicted activity spectrum of a compound as probable activity (Pa) and probable inactivity (Pi) as described by Goel *et al.* (2011)<sup>[28]</sup> and we used Pa>0.3.

## Results and Discussion

We successfully revealed pharmacokinetics, drug-likeness, biological activity predictions of the various phytochemicals from *Garcinia mangostana* L. All phytochemicals predicted as high in pharmacokinetics prediction (gastrointestinal absorption), except Garcinone E. In addition, all phytochemicals predicted fulfill all Lipinski rule-of-five. Furthermore, 18 phytochemicals of *Garcinia mangostana* L. predicted as antioxidant, anti-inflammatory, and antineoplastic activity.

In addition, phytochemical screening, based on ethnomedicinal data, is considered as an effective approach for the discovery of new therapeutic agents. The major bioactive secondary metabolites of mangosteen are xanthone derivatives<sup>[1,4]</sup>. The major constituents from the xanthone fraction in mangosteen were found to be  $\alpha$ -mangostin and  $\gamma$ -mangostin<sup>[4,14]</sup>. More than 60 other xanthones are isolated from its different plant parts of including 3-isomangostin,  $\beta$ -mangostin, gartanin, mangostanin, 1-isomangostin, garcinone B, 9-hydroxycalabaxanthone, mangostanol, mangostinone demethylcalabaxanthone, 8-deoxygartanin, and garcinone D<sup>[1]</sup>. The majority of investigations are focused on the extraction and structure elucidation of xanthones from the pericarp of mangosteen<sup>[14]</sup>. Recently, the presence of these compounds in the stem, seed, and heartwood was reported by many authors<sup>[9,11,19,20,23,24,25]</sup>.

On the other hand, bioinformatics provides more

efficient target discovery and validation approaches, thus help to ensure that more drug candidates are successful during the approval process and making it more cost-effective<sup>[26]</sup>. Notably, the work of Lipinski *et al.* analyzed orally active constituents to describe physicochemical ranges for high probability opportunities to be an oral drug. This called rule-of-five delineated the relationship between pharmacokinetics and physicochemical parameters. Lipinski rule-of-five helps in distinguishing between drug-like and non-drug like molecules. It predicts a high probability of success or failure due to drug-likeness for molecules complying with 2 or more of the following rules, such as molecular mass less than 500 Dalton, high lipophilicity, less than 5 hydrogen bond donors, less than 10 hydrogen bond acceptors, molar refractivity should be between 40-130<sup>[27]</sup>.

In this study, an attempt has been made to investigate a more extensive pharmacological appearance of phytoconstituents by application of PASS web resources. The proposed *in silico* method extends further to generate novel bioactivities of selected phytochemical leads, related side-effects, and their mechanisms. In addition, the recent version of PASS predicts approximately 3750 pharmacological activities, specific toxicities, biochemical mechanisms of action, and metabolic terms on the basis of the structural formula of drug-like substances with average fidelity ~95%. This might be further validated *in vitro* as well as *in vivo* trials<sup>[28]</sup>. In line with this, the present study revealed the use of PASS for exploring the hidden pharmacological potential of the various phytochemicals from the mangosteen.

## Conclusion

In summary, we revealed the biological activity of 18 phytochemicals of the mangosteen. However, further trials, such as *in vitro* and *in vivo* evaluation, are needed to prove the validity of these findings.

**Conflict of Interest:** The authors declare that they have no conflict of interest.

**Source of Funding :** This study supported by the PMDSU Scholarship (Batch III) from the Ministry of Education and Culture of the Republic of Indonesia.

**Acknowledgements:** Viol Dhea Kharisma (Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Indonesia) for the help and cooperation in carrying out this study. We thank EJA, Indonesia, for editing the manuscript. We would like to declare our sympathy to the victims of COVID-19. Tribute goes to the frontliners worldwide, especially in Indonesia.

**Ethical Approval:** No ethical approval needed.

### References

1. Ansori ANM, et al. A review on medicinal properties of mangosteen (*Garcinia mangostana* L.). *Research Journal of Pharmacy Technology*. 2020; 13(2): 974-982.
2. Fadholly A, et al. Apoptosis of HeLa cells via caspase-3 expression induced by chitosan-based nanoparticles of *Annona squamosa* leaf extract: In vitro study. *Indian Journal of Pharmaceutical Education and Research*. 2020; 54(2): 416-421.
3. Husen SA, et al. Renal protective effects of gamma-mangostin in streptozotocin-induced diabetic mice. *Indian Journal of Forensic Medicine and Toxicology*. 2020; 14(3): 1221-1226.
4. Ansori ANM, et al. Antidiabetes type 2 phytomedicine: Mangosteen (*Garcinia mangostana* L.) - A review. *Biochemical and Cellular Archives*. 2020; 20: 3173-3177.
5. Susilo RJK, et al. The effect of *Garcinia mangostana* extract on ALT and AST levels and liver structure in streptozotocin-induced diabetic mice. *Annals of Biology*. 2020; 36(2): 149-153.
6. Husen SA, et al. Hepato-renal protective effects of mangosteen (*Garcinia mangostana* L.) pericarp extract in streptozotocin-induced diabetic mice. *Journal of Physics: Conference Series*. 2020; 1445(1): 012018.
7. Sharma PHB, et al. A historical and taxonomic overview of *Garcinia* L. and its reproductive ecology. *Folia Malaysiana*. 2013; 14(1): 63-76.
8. Sobir, et al. comparison analysis of genetic diversity of Indonesian mangosteens (*Garcinia mangostana* L.) and related species by means isozymes and AFLP markers. *Biodiversitas*. 2009; 10(4): 163-167.
9. Pedraza-Chaverri J, et al. Medicinal properties of mangosteen (*Garcinia mangostana*). *Food and Chemical Toxicology*. 2008; 46(10): 3227-3239.
10. Chin YW, et al. Xanthones with quinone reductase-inducing activity from the fruits of *Garcinia mangostana* (mangosteen). *Phytochemistry*. 2008; 69: 754-758.
11. Gutierrez-Orozco F and Failla ML. Biological activities and bioavailability of mangosteen xanthones: a critical review of the current evidence. *Nutrients*. 2013; 5(8): 3163-83.
12. Husen SA, et al. Activity assay of mangosteen (*Garcinia mangostana* L.) pericarp extract for decreasing fasting blood cholesterol level and lipid peroxidation in type-2 diabetic mice. *AIP Conference Proceedings*. 2017; 1888(1): 020026-1-6.
13. Husen SA, et al. Antioxidant and antidiabetic activity of *Garcinia mangostana* L. pericarp extract in streptozotocin-induced diabetic mice. *Bioscience Research*. 2017; 14(4): 1238-1245.
14. Ansori ANM, et al. Renoprotection by *Garcinia mangostana* L. pericarp extract in streptozotocin-induced diabetic mice. *Iraqi Journal of Veterinary Sciences*. 2019; 33(1): 13-19.
15. Jung HA, et al. Antioxidant xanthones from the pericarp of *Garcinia mangostana* (mangosteen). *Journal of Agricultural and Food Chemistry*. 2006; 54(6): 2077-2082.
16. Husen SA, et al. Antioxidant activity assay of alpha-mangostin for amelioration of kidney structure and function in diabetic mice. *Advances in Social Science, Education and Humanities Research (ASSEHR)*. 2018; 98: 84-88.
17. Husen SA, et al. Hepatoprotective effect of gamma-mangostin for amelioration of impaired liver structure and function in streptozotocin-induced diabetic mice. *IOP Conference Series: Earth and Environmental Science*. 2019; 217: 012031.
18. Chairungsrilerd N, et al. Pharmacological properties of alpha-mangostin, a novel histamine H1 receptor antagonist. *European Journal of Pharmacology*. 1996; 314(3): 351-356.
19. Chin YW and Kinghorn AD. Structural characterization, biological effects, and synthetic studies on xanthones from mangosteen (*Garcinia mangostana*), a popular botanical dietary supplement. *Mini-Reviews in Organic Chemistry*. 2008; 5(4): 355-364.
20. Huang YL, et al. Three xanthones and a

- benzophenone from *Garcinia mangostana*. *Journal of Natural Products*. 2001; 64(7): 903-906.
21. Suksamrarn S, et al. Antimycobacterial activity of prenylated xanthenes from the fruits of *Garcinia mangostana*. *Chemical & Pharmaceutical Bulletin*. 2003; 51(7): 857-859.
  22. Suksamrarn S, et al. Cytotoxic prenylated xanthenes from the young fruit of *Garcinia mangostana*. *Chemical & Pharmaceutical Bulletin*. 2006; 54(3): 301-305.
  23. Ryu HW, et al.  $\alpha$ -Glucosidase inhibition and antihyperglycemic activity of prenylated xanthenes from *Garcinia mangostana*. *Phytochemistry*. 2011; 72(17): 2148-2154.
  24. Nelli GB, et al. Antidiabetic effect of  $\alpha$ -mangostin and its protective role in sexual dysfunction of streptozotocin induced diabetic male rats. *Systems Biology in Reproductive Medicine*. 2013; 59(6): 319-328.
  25. Jariyapongskul A, et al. Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats. 2015; 2015: 785826.
  26. Daina A, et al. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*. 2017; 7: 42717.
  27. Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 2001; 46(1-3): 3-26.
  28. Goel RK, et al. PASS-assisted exploration of new therapeutic potential of natural products. *Medicinal Chemistry Research*. 2011; 20: 1509-1514.